Education
About Us
Working with TipRanks
Follow Us
MabCure (MBCI)
:MBCI
MBCI Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume1.00K
Average Volume (3M)8.62K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-22.70
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding64,364,000
10 Day Avg. Volume1,542
30 Day Avg. Volume8,622
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
MBCI FAQ
What was MabCure ’s price range in the past 12 months?
MabCure lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is MabCure ’s market cap?
Currently, no data Available
When is MabCure ’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MabCure ’s earnings last quarter?
Currently, no data Available
Is MabCure overvalued?
According to Wall Street analysts MabCure ’s price is currently Overvalued.
Does MabCure pay dividends?
MabCure does not currently pay dividends.
What is MabCure ’s EPS estimate?
MabCure ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MabCure have?
MabCure has 64,364,000 shares outstanding.
What happened to MabCure ’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MabCure ?
Currently, no hedge funds are holding shares in MBCI
Company Description
MabCure
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.
Technical Analysis
Ascent Solar Technologies
―
AquaBounty Technologies
―
Auddia
―
SaverOne 2014 Ltd. ADR
―
Wearable Devices Ltd.
―